ReviewBlood purification2021
COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors.
Review in Blood purification, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 24 citations in OpenAlex.
- Prevalence of arrhythmias and associated factors among COVID-19 patients in the intensive care unit at COVID-19 treatment centers, Addis Ababa, Ethiopia, 2022. A cross-sectional study.BMC infectious diseases · 2025Article
- COVID-19 and cardiovascular disease in patients with chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Review
- Attitude and influencing factors to receive the COVID-19 vaccine among university students in Sichuan Province, China: A cross-sectional study.Nursing open · 2023Article
- Drug-Disease Severity and Target-Disease Severity Interaction Networks in COVID-19 Patients.Pharmaceutics · 2022Article
- Clinical management of COVID-19 in hospitals and the community: A snapshot from a medical insurance database in South Africa.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- [Long-term physical and psychological consequences of chronic kidney disease].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022Review
- The evolving direct and indirect platforms for the detection of SARS-CoV-2.Journal of virological methods · 2022Review
- Modelling COVID-19 transmission in a hemodialysis centre using simulation generated contacts matrices.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is a frequent complication and the most common cause of death in patients with CKD. Despite landmark medical advancements, mortality due to cardiovascular disease is still 20 times higher in CKD patients than in the general population, which is mainly due to the high prevalence of risk factors in this group. Indeed, in addition to traditional cardiovascular risk factors, CKD patients are exposed to nontraditional ones, which include metabolic, hormonal, and inflammatory alterations. The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought novel challenges for both cardiologists and nephrologists alike. Emerging evidence indicates that coronavirus disease 2019 (COVID-19) increases the risk of cardiovascular events and that several aspects of the disease may synergize with pre-existing cardiovascular risk factors in CKD patients. A better understanding of these mechanisms is pivotal for the prevention and treatment of cardiovascular events in this context, and we believe that additional clinical and experimental studies are needed to improve cardiovascular outcomes in CKD patients with COVID-19. In this review, we provide a summary of traditional and nontraditional cardiovascular risk factors in CKD patients, discussing their interaction with SARS-CoV-2 infection and focusing on CO-VID-19-related cardiovascular complications that may severely affect short- and long-term outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.